Anbio Biotechnology
NNNNNasdaq
$9.49
↓ -1.1%Jul 17 close · end-of-day
Price
1Y↓ -79.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$414.4M
Enterprise Value
$402.5M
P/E
64.6
P/S
47.9
P/B
13.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$8.6M
Net Income (TTM)
$6.4M
Free Cash Flow (TTM)
—
Gross Margin
87.2%
Operating Margin
66.7%
Net Margin
74.1%
ROE
21.2%
ROIC
31.6%
Debt / Equity
—
Net Cash
$11.9M
Return 1Y
-78.3%
Company profile
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our principal executive offices are located at Wilhelm Gutbrod Str 21B, 60437, Frankfurt am Main, Germany.
- CEO
- Michael Lau
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 27
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $23.5M | $6.7M | $8.2M | $8.6M |
| Gross profit | $12.6M | $3.4M | $5.9M | $7.5M |
| Operating income | $10.2M | $2.0M | $2.0M | $5.8M |
| Net income | $10.0M | $2.3M | $2.4M | $6.4M |
| Diluted EPS | $100,112.00 | $0.11 | $0.06 | $0.15 |
| Operating cash flow | $4.4M | $898,367.00 | $2.1M | -$6.7M |
| Free cash flow | — | — | — | — |
| Gross margin | 53.4% | 50.1% | 71.9% | 87.2% |
| Operating margin | 43.3% | 29.2% | 24.4% | 66.7% |
| Net margin | 42.5% | 33.6% | 29.0% | 74.1% |
No quarterly data.
Company news
May 29, 2026
May 21, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.